deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT02766335

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study)

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Squamous Cell Lung Carcinoma Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions Docetaxel Durvalumab Laboratory Biomarker Analysis
Updated 14 times since 2017 Last updated: May 2, 2023 Started: Jul 31, 2014 Primary completion: Sep 30, 2018 Completion: Sep 30, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02766335, this PHASE2/PHASE3 trial focuses on Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7 and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 14 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Mar 2020 · 13 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~May 2023 · 16 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. May 2023 — Jun 2023 [monthly]

    Completed PHASE2_PHASE3

▶ Show 9 earlier versions

  1. Jan 2022 — May 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Feb 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  6. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Phase: PHASE2 → PHASE2_PHASE3

  7. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  8. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Albany, United States , Amarillo, United States , American Fork, United States , Ames, United States , Anacortes, United States , Anaheim, United States , Anchorage, United States , Anderson, United States , Ann Arbor, United States and 570 more locations